Trial Profile

Clinical study of Celecoxib/ciprofloxacin in Parkinson's disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib/ciprofloxacin (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Biomarker; Pharmacodynamics

Most Recent Events

16 Aug 2023 According to a NeuroSense Therapeutics media release,The Company is exploring potential co-development for the PD indication.
06 Jul 2023 Status changed from recruiting to completed, according to a NeuroSense Therapeutics media release.
01 Jun 2023 Results evaluating the potential of its combination platform therapy for the treatment of PD, presented in a NeuroSense Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com